Alpha 2.0
Login Register
» Authors » Vijay Maruti Patil

Vijay Maruti Patil

Explore the profile of Vijay Maruti Patil including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 44
Citations 590
Followers 0
Related Specialties
Oncology
Pharmacology
Dentistry
Top 10 Co-Authors
Kumar Prabhash
Vanita Noronha
Amit Joshi
Nandini Menon
Abhishek Mahajan
Atanu Bhattacharjee
Sarbani Ghosh-Laskar
Nilendu Purandare
Pankaj Chaturvedi
Shripad Banavali
Published In
J Clin Oncol
South Asian J Cancer
J Natl Cancer Inst
Oral Oncol
Indian J Surg Oncol
Affiliations
Soon will be listed here.
Recent Articles
1.
Compartmentalization of High Infratemporal Fossa in Oral Cavity Squamous Cell Carcinomas and Its Impact on Clinical Outcome
Mahajan A, Agarwal U, Ashtekar R, Chakrabarty N, Vaish R, Patil V, et al.
Curr Oncol . 2025 Feb; 32(2). PMID: 39996899
Background: According to the 8th edition of the American Joint Committee on Cancer (AJCC), involvement of the masticator space and infratemporal fossa (ITF) in oral cancers indicates advanced disease (T4b),...
2.
A Novel Deep Learning-Based (3D U-Net Model) Automated Pulmonary Nodule Detection Tool for CT Imaging
Mahajan A, Agarwal R, Agarwal U, Ashtekar R, Komaravolu B, Madiraju A, et al.
Curr Oncol . 2025 Feb; 32(2). PMID: 39996895
Background: Precise detection and characterization of pulmonary nodules on computed tomography (CT) is crucial for early diagnosis and management. Objectives: In this study, we propose the use of a deep...
3.
Deep Diving Into the Fusion Across Cancer Types in the Indian Population From Formalin-Fixed Paraffin-Embedded RNA-Exome Data: A Road to Discovering Novel Rearrangements With Clinical Relevance
Khuntia S, Mukherjee N, Javle V, Tanwar N, Sreekanthreddy P, Varghese L, et al.
JCO Glob Oncol . 2024 Nov; 10:e2400289. PMID: 39571115
Purpose: Gene fusions are critical oncogenic mutations that drive cancer development and serve as diagnostic and prognostic biomarkers. Despite the increasing cancer burden in India, large-scale analyses of molecular landscapes,...
4.
Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinoma
Noronha V, Patil V, Menon N, Joshi A, Shah M, Singh A, et al.
J Natl Cancer Inst . 2024 Sep; 117(1):58-75. PMID: 39222012
Background: Standard neoadjuvant chemotherapy for locally advanced esophageal or gastroesophageal junction squamous cancer, 5-fluorouracil plus platinum, is toxic and logistically challenging; alternative regimens are needed. Methods: This was a phase...
5.
Phase III randomized trial comparing palliative systemic therapy to best supportive care in advanced esophageal/GEJ cancer
Noronha V, Patil V, Menon N, Goud S, Singh A, Shah M, et al.
Int J Cancer . 2024 Aug; 155(12):2232-2245. PMID: 39093841
No study has unequivocally proven that chemotherapy prolongs overall survival (OS) in advanced esophageal cancer. We conducted a Phase III randomized study in first-line advanced unresectable/metastatic esophageal/GEJ cancer. Patients aged...
6.
Deep-Learning-Based Predictive Imaging Biomarker Model for EGFR Mutation Status in Non-Small Cell Lung Cancer from CT Imaging
Mahajan A, Kania V, Agarwal U, Ashtekar R, Shukla S, Patil V, et al.
Cancers (Basel) . 2024 Mar; 16(6). PMID: 38539465
Purpose: The authors aimed to develop and validate deep-learning-based radiogenomic (DLR) models and radiomic signatures to predict the EGFR mutation in patients with NSCLC, and to assess the semantic and...
7.
A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC
Noronha V, Menon N, Patil V, Chandrakanth M, More S, Dhanawat A, et al.
JTO Clin Res Rep . 2024 Jan; 5(1):100622. PMID: 38292414
Introduction: The outcomes in advanced NSCLC have improved owing to the availability of more effective systemic and improved supportive care. This has increased the number of patients who seek treatment...
8.
Understanding the Impact of Population and Cancer Type on Tumor Mutation Burden Scores: A Comprehensive Whole-Exome Study in Cancer Patients From India
Tanwar N, Malhotra R, Satheesh A, Khuntia S, Sreekanthreddy P, Varghese L, et al.
JCO Glob Oncol . 2023 Dec; 9:e2300047. PMID: 38085046
Purpose: The purpose of this study was to understand the impact of population diversity and geographic variation on tumor mutation burden (TMB) scores across cancers and its implication on stratification...
9.
Real-World Evidence of EGFR Targeted Therapy in NSCLC- A Brief Report of Decade Long Single Center Experience
Chougule A, Chandrani P, Noronha V, Pange P, Kale S, Nikam A, et al.
JTO Clin Res Rep . 2023 Nov; 4(11):100566. PMID: 38033811
The significance of EGFR targeted therapy in the lung adenocarcinoma is paramount. Several controlled clinical trials have reported considerable survival of EGFR mutation positive patients on receiving the EGFR tyrosine...
10.
Long-term outcomes of neo-adjuvant chemotherapy on borderline resectable oral cavity cancers: Real-world data of 3266 patients and implications for clinical practice
Noronha V, Dhanawat A, Patil V, Menon N, Singh A, Chaturvedi P, et al.
Oral Oncol . 2023 Nov; 148:106633. PMID: 37988838
Background: Neo-adjuvant chemotherapy (NACT) followed by response assessment is the standard treatment algorithm for locally advanced oral cavity squamous cell carcinomas (OCSCC) in the Indian subcontinent. The 3-drug NACT regimen...